Most Read Articles
2 days ago
Eating behaviours have been shown to moderate the relationship between cumulated risk factors in the first 1,000 days and adiposity outcomes at 6 years of age, which underscores modifiable behavioural targets for interventions, reports a study.
Tristan Manalac, 4 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
2 days ago
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.
Audrey Abella, 3 days ago
A novel, investigational vaginal pH regulator (VPR) – a nonhormonal, water-based, petroleum-free contraceptive vaginal gel – improved genitourinary (GU) side effects and sexual satisfaction in women who are at risk of pregnancy but are not aiming to conceive, interim findings from the phase III AMPOWER* trial show.

Product Highlight - Zavicefta

29 Nov 2019

Active ingredient: Ceftazidime (as pentahydrate) equivalent to 2 g and Avibactam (as sodium salt) equivalent to 0.5 g.

Indications: ZAVICEFTATM is indicated in adults for the treatment of the following infections

  • Complicated Intra-Abdominal Infection (cIAI)
  • Complicated Urinary Tract Infection, including Pyelonephritis (cUTI)
  • Hospital-acquired Pneumonia (HAP), including ventilator associated pneumonia (VAP)
  • Infections due to aerobic Gram-negative organisms in patients with limited treatment options
  • Consideration should be given to official guidance on the appropriate use of antibacterial agents. For treatment of cIAI use in combination with metronidazole.

Dosage & Administration: The recommended dosage of ZAVICEFTATM is 1 vial where each vial contains 2 g ceftazidime and 0.5 g avibactam administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes in patients aged 18 years or older. Treatment is repeated every 8 hours.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Eating behaviours have been shown to moderate the relationship between cumulated risk factors in the first 1,000 days and adiposity outcomes at 6 years of age, which underscores modifiable behavioural targets for interventions, reports a study.
Tristan Manalac, 4 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
2 days ago
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.
Audrey Abella, 3 days ago
A novel, investigational vaginal pH regulator (VPR) – a nonhormonal, water-based, petroleum-free contraceptive vaginal gel – improved genitourinary (GU) side effects and sexual satisfaction in women who are at risk of pregnancy but are not aiming to conceive, interim findings from the phase III AMPOWER* trial show.